
Priority Technology Holdings, Inc. Reports First Quarter Financial Results
"Strong first quarter growth in revenue and profits continues to demonstrate the value of our Priority Commerce Engine, purpose built to help our customers accelerate cash flow and optimize working capital. We delivered consistent results across each of our SMB Acquiring, B2B Payables and Enterprise Payments segments," said Tom Priore, Chairman & CEO of Priority. 'The blend of the diverse and counter-cyclical aspects of our platform combined with relentless execution to gain market share in traditional payment segments reinforces that Priority's technology, operations and vision have positioned us to excel through the remainder of 2025 and beyond despite an uncertain macro-economic environment.'
Highlights of Consolidated Results
First Quarter 2025 Financial Highlights compared with First Quarter 2024 1
Revenue of $224.6 million increased 9.2% from $205.7 million
Adjusted gross profit (a non-GAAP measure 2) of $87.3 million increased 14.2% from $76.4 million
Adjusted gross profit margin (a non-GAAP measure 2) of 38.9% increased 170 basis points from 37.1%
Operating income of $32.6 million increased 16.4% from $28.0 million
Adjusted EBITDA (a non-GAAP measure 2) of $51.3 million increased 10.7% from $46.3 million
Adjusted EPS (a non-GAAP measure 2) of $0.22 increased by $0.19, or 633.3%, from $0.03
(1)
Certain amounts/percentages may not compute accurately due to rounding.
(2)
See "Non-GAAP Financial Measures" and the reconciliations of Adjusted Gross Profit (non-GAAP), Adjusted Gross Profit Margin (non-GAAP), Adjusted EBITDA, and Adjusted EPS (non-GAAP) to their most comparable GAAP measures provided within this document for additional information.
Expand
Full Year 2025 Financial Guidance
Priority's outlook remains strong and we affirm our full year 2025 guidance as follows:
Revenue forecast to range between $965 million to $1 billion, a growth rate of 10% to 14%, compared to fiscal 2024 results
Adjusted gross profit (a non-GAAP measure) forecast to range between $360 million and $385 million, a growth rate of 10% to 17% compared to fiscal 2024 results
Adjusted EBITDA (a non-GAAP measure) forecast to range between $220 million to $230 million, a growth rate of 8% to 13% compared to fiscal 2024 results
Conference Call
The Company will host a conference call on Tuesday, May 6, 2025 at 11:00 a.m. EST to discuss its first quarter financial results. Participants can access the call by phone in the U.S. or Canada at (877) 407-0752 or internationally at (201) 389-0912.
The Internet webcast link and accompanying slide presentation can be accessed at https://viavid.webcasts.com/starthere.jsp?ei=1717257&tp_key=17b579fc0a and will also be posted in the "Investor Relations" section of the Company's website at www.prioritycommerce.com/investors.
An audio replay of the call will be available shortly after the conference call until May 20, 2025, at 11:59 p.m. ET. To listen to the audio replay, dial (844) 512-2921 or (412) 317-6671 and enter conference ID number 13753537. Alternatively, you may access the webcast replay in the "Investor Relations" section of the Company's website at www.prioritycommerce.com/investors.
Non-GAAP Financial Measures
This communication includes certain non-GAAP financial measures that we regularly review to evaluate our business and trends, measure our performance, prepare financial projections, allocate resources, and make strategic decisions. We believe these non-GAAP measures help to illustrate the underlying financial and business trends relating to our results of operations and comparability between current and prior periods. We also use these non-GAAP measures to establish and monitor operational goals. However, these non-GAAP measures are not superior to or a substitute for prominent measurements calculated in accordance with GAAP. Rather, the non-GAAP measures are meant to be a complement to understanding measures prepared in accordance with GAAP.
The Company's adjusted gross profit metric represents revenues less cost of revenue (excluding depreciation and amortization). Adjusted gross profit margin is adjusted gross profit divided by revenues. We review these non-GAAP measures to evaluate our underlying profit trends. The reconciliation of adjusted gross profit to its most comparable GAAP measure is provided below:
EBITDA and Adjusted EBITDA
EBITDA and adjusted EBITDA are performance measures. EBITDA is earnings before interest, income tax, and depreciation and amortization expenses ("EBITDA"). Adjusted EBITDA begins with EBITDA but further excludes certain non-cash costs, such as stock-based compensation and the write-off of the carrying value of investments or other assets, as well as debt extinguishment and modification expenses and other expenses and income items considered non-recurring, such as acquisition integration expenses, certain professional fees, and litigation settlements. We review the non-GAAP adjusted EBITDA measure to evaluate our business and trends, measure our performance, prepare financial projections, allocate resources, and make strategic decisions.
The reconciliation of adjusted EBITDA to its most comparable GAAP measure is provided below:
Further detail of certain of these adjustments, and where these items are recorded in our consolidated statements of operations, is provided below:
Adjusted Earnings Per Share (Adjusted EPS)
Adjusted EPS is a performance measure. Adjusted EPS is calculated by dividing adjusted net income (loss) attributable to common shareholders by weighted average number shares outstanding for the respective periods.
Adjusted net income attributable to common shareholders begins with net income (loss) attributable to common shareholders adjusted to exclude various items listed below. We believe that adjusted EPS is a measure that is useful to investors and management in understanding our ongoing profitability and in analysis of ongoing profitability trends.
(1)
The tax impact calculated using the blended statutory income tax rate adjusted for discrete items (27.1% and 26.0% for the three months ended March 31, 2025 and March 31, 20204, respectively.)
Expand
Priority does not provide a reconciliation of forward-looking non-GAAP financial measures to their comparable GAAP financial measures because it could not do so without unreasonable effort due to the unavailability of the information needed to calculate reconciling items and due to the variability, complexity and limited visibility of the adjusting items that would be excluded from the non-GAAP financial measures in future periods. When planning, forecasting and analyzing future periods, the Company does so primarily on a non-GAAP basis without preparing a GAAP analysis as that would require estimates for various cash and non-cash reconciling items that would be difficult to predict with reasonable accuracy. For example, stock-based compensation expense would be difficult to estimate because it depends on the Company's future hiring and retention needs, as well as the future fair market value of the Company's common stock, all of which are difficult to predict and subject to constant change. As a result, the Company does not believe that a GAAP reconciliation would provide meaningful supplemental information about the Company's outlook.
About Priority Technology Holdings, Inc.
Priority is a solution provider in Payments and Banking as a Service operating at scale with over 1.3 million active customers across its SMB, B2B and Enterprise channels processing approximately $135.0 billion in annual transaction volume and providing administration for over $1.3 billion in account balances. Priority is the payments and banking fintech that streamlines collecting, storing, lending, and sending money through its innovative commerce engine to unlock revenue and generate operational success for businesses. Additional information can be found at www.prioritycommerce.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations and intentions with respect to future operations, products and services, and other statements identified by words such as "may," "will," "should," "anticipates," "believes," "expects," "plans," "future," "intends," "could," "estimate," "predict," "projects," "targeting," "potential" or "contingent," "guidance," "outlook" or words of similar meaning. These forward-looking statements include, but are not limited to, our 2025 outlook and statements regarding our market and growth opportunities. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive risks, trends and uncertainties that could cause actual results to differ materially from those projected, expressed, or implied by such forward-looking statements. Our actual results could differ materially, and potentially adversely, from those discussed or implied herein.
We caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. You should evaluate all forward-looking statements made in this press release in the context of the risks and uncertainties disclosed in our SEC filings, including our most recent Annual Report on Form 10-K filed with the SEC on March 6, 2025. These filings are available online at www.sec.gov or www.prioritycommerce.com.
We caution you that the important factors referenced above may not contain all of the factors that are important to you. In addition, we cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences we anticipate or affect us or our operations in the way we expect. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance. The forward-looking statements included in this press release are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. If we do update one or more forward-looking statements, no inference should be made that we will make additional updates with respect to those or other forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements.
(1)
Adjusted EPS in a non-GAAP earnings measure. See Adjusted EPS reconciliation for further detail.
Expand
Priority Technology Holdings, Inc.
Unaudited Consolidated Balance Sheets
(in thousands)
March 31, 2025
December 31, 2024
Assets
Current assets:
Cash and cash equivalents
$
47,587
$
58,600
Restricted cash
11,490
11,090
Accounts receivable, net of allowances
80,280
67,969
Prepaid expenses and other current assets
19,962
22,990
Current portion of notes receivable, net of allowance
2,231
3,638
Settlement assets and customer/subscriber account balances
1,003,034
940,798
Total current assets
1,164,584
1,105,085
Notes receivable, less current portion
6,473
4,919
Property, equipment and software, net
53,718
52,477
Goodwill
386,822
376,091
Intangible assets, net
231,560
240,874
Deferred income taxes, net
26,933
24,697
Other noncurrent assets
21,568
22,717
Total assets
$
1,891,658
1,826,860
Liabilities, Stockholders' Deficit and NCI
Current liabilities:
Accounts payable and accrued expenses
$
54,414
$
62,149
Accrued residual commissions
40,478
37,560
Customer deposits and advance payments
2,506
2,246
Current portion of long-term debt
1,879
9,503
Settlement and customer/subscriber account obligations
1,003,395
940,213
Total current liabilities
1,102,672
1,051,671
Long-term debt, net of current portion, discounts and debt issuance costs
918,944
920,888
Other noncurrent liabilities
26,467
19,326
Total liabilities
2,048,083
1,991,885
Stockholders' deficit:
Preferred stock
—
—
Common stock
80
77
Treasury stock, at cost
(21,077
)
(19,607
)
Additional paid-in capital
1,669
—
Accumulated other comprehensive loss
(133
)
(176
)
Accumulated deficit
(138,866
)
(147,134
)
Total stockholders' deficit attributable to stockholders of Priority
(158,327
)
(166,840
)
Non-controlling interests in consolidated subsidiaries
1,902
1,815
Total stockholders' deficit
(156,425
)
(165,025
)
Total liabilities, stockholders' deficit and NCI
$
1,891,658
$
1,826,860
Expand
Priority Technology Holdings, Inc.
Unaudited Consolidated Statements of Cash Flows
(in thousands)
Three Months Ended March 31,
2025
2024
Cash flows from operating activities:
Net income
$
8,268
$
5,193
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization of assets
13,777
15,253
Stock-based, ESPP and incentive units compensation
1,586
1,633
Amortization of debt issuance costs and discounts
434
1,065
Debt extinguishment and modification costs
38
—
Deferred income tax
(2,236
)
(1,872
)
Change in contingent consideration
1,006
972
Other non-cash items, net
(20
)
(259
)
Change in operating assets and liabilities:
Accounts receivable
(12,182
)
(8,339
)
Prepaid expenses and other current assets
(73
)
(425
)
Income taxes (receivable) payable
4,429
—
Notes receivable
—
(266
)
Accounts payable and other accrued liabilities
(5,796
)
1,590
Customer deposits and advance payments
260
157
Other assets and liabilities, net
465
(1,395
)
Net cash provided by operating activities
9,956
13,307
Cash flows from investing activities:
Acquisition of business, net of cash acquired
(4,473
)
—
Additions to property, equipment and software
(5,095
)
(6,610
)
Notes receivable, net
(147
)
(1,059
)
Net cash used in investing activities
(9,715
)
(7,669
)
Cash flows from financing activities:
Debt issuance and modification costs paid
(40
)
—
Repayments of long-term debt
(10,000
)
(1,678
)
Repurchases of shares withheld for taxes
(1,470
)
(421
)
Dividends paid to redeemable senior preferred stockholders
—
(7,027
)
Proceeds from exercise of stock options
110
—
Settlement and customer/subscriber accounts obligations, net
59,060
1,918
Payment of contingent consideration related to business combination
(400
)
(3,071
)
Net cash provided by (used in) financing activities
47,260
(10,279
)
Net change in cash and cash equivalents and restricted cash:
Net increase in cash and cash equivalents, and restricted cash
47,501
(4,641
)
Cash and cash equivalents and restricted cash at beginning of period
993,864
796,223
Cash and cash equivalents and restricted cash at end of period
$
1,041,365
$
791,582
Reconciliation of cash and cash equivalents, and restricted cash:
Cash and cash equivalents
$
47,587
$
34,290
Restricted cash
11,490
12,658
Cash and cash equivalents included in settlement assets and customer/subscriber account balances (restricted in nature)
982,288
744,634
Total cash and cash equivalents, and restricted cash
$
1,041,365
$
791,582
Expand
Priority Technology Holdings, Inc.
Unaudited Reportable Segments' Results
(in thousands)
Three Months Ended March 31,
2025
2024
SMB Payments:
Revenues
$
151,690
$
144,005
Adjusted EBITDA
$
25,705
$
25,023
Key Indicators:
Merchant bankcard processing dollar value
$
15,294,133
$
14,788,095
Merchant bankcard transaction count
185,539
175,228
Total card processing dollar value
$
17,685,491
$
17,098,758
B2B Payments:
Revenues
$
23,918
$
21,344
Adjusted EBITDA
$
3,516
$
1,747
Key Indicators:
B2B issuing dollar volume
$
237,290
$
227,811
B2B issuing transaction count
211
240
Enterprise Payments:
Revenues
$
50,088
$
40,990
Adjusted EBITDA
$
42,442
$
34,727
Key Indicators:
Average CFTPay billed clients
940,463
703,887
Average CFTPay monthly new enrollments
55,946
53,551
Expand
Priority Technology Holdings, Inc.
Unaudited Reportable Segments' Results
(in thousands)
Three Months Ended March 31, 2025
SMB Payments
B2B Payments
Enterprise Payments
Corporate
Total Consolidated
Reconciliation of Adjusted EBITDA to GAAP Measure:
Adjusted EBITDA
$
25,705
$
3,516
$
42,442
$
(20,369
)
$
51,294
Interest expense
—
(1,006
)
—
(22,170
)
(23,176
)
Depreciation and amortization
(6,625
)
(1,261
)
(4,642
)
(1,249
)
(13,777
)
Debt modification and extinguishment expenses
—
—
—
(38
)
(38
)
Selling, general and administrative (non-recurring)
—
—
—
(2,199
)
(2,199
)
Non-cash stock based compensation
(4
)
(84
)
(32
)
(1,466
)
(1,586
)
Income (loss) before taxes
$
19,076
$
1,165
$
37,768
$
(47,491
)
$
10,518
Income tax expense
(2,250
)
Net Income
$
8,268
Expand
Three Months Ended March 31, 2024
Reconciliation of Adjusted EBITDA to GAAP Measure:
Adjusted EBITDA
$
25,023
$
1,747
$
34,727
$
(15,157
)
$
46,340
Interest expense
(1
)
(973
)
—
(19,906
)
(20,880
)
Depreciation and amortization
(8,586
)
(1,470
)
(4,039
)
(1,158
)
(15,253
)
Selling, general and administrative (non-recurring)
—
—
—
(798
)
(798
)
Non-cash stock based compensation
(4
)
(118
)
(32
)
(1,480
)
(1,634
)
Income (loss) before taxes
$
16,432
$
(814
)
$
30,656
$
(38,499
)
$
7,775
Income tax expense
(2,582
)
Net Income
$
5,193
Expand
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
16 minutes ago
- Business Wire
Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Today, Sarepta Therapeutics notified the U.S. Food and Drug Administration (FDA) of its decision to voluntarily and temporarily pause all shipments of ELEVIDYS (delandistrogene moxeparvovec) for Duchenne muscular dystrophy in the United States, effective close of business Tuesday, July 22, 2025. This proactive step will allow Sarepta the necessary time to respond to any requests for information and allow Sarepta and FDA to complete the ELEVIDYS safety labeling supplement process. The Company looks forward to a collaborative, science-driven review process and dialogue with the FDA. 'As a patient-centric organization, the decision to voluntarily and temporarily pause shipments of ELEVIDYS was a painful one, as individuals with Duchenne are losing muscle daily and in need of disease-modifying options,' said Doug Ingram, chief executive officer, Sarepta. 'It is important for the patients we serve that Sarepta maintains a productive and positive working relationship with FDA, and it became obvious that maintaining that productive working relationship required this temporary suspension while we address any questions that FDA may have and complete the ELEVIDYS label supplement process.' Sarepta remains committed to transparency and patient safety and will continue to provide timely updates to patients, families, healthcare providers, and the broader Duchenne community as additional information becomes available. About ELEVIDYS (delandistrogene moxeparvovec-rokl) ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS: Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Forward-Looking Statements This statement contains 'forward-looking statements.' Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'will,' 'may,' 'intend,' 'prepare,' 'look,' 'potential,' 'possible' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, ELEVIDYS, ongoing interactions with FDA related to ELEVIDYS, and our decision to voluntarily and temporarily pause shipments of ELEVIDYS in the United States. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; different methodologies, assumptions and applications we use to assess particular safety or efficacy parameters may yield different statistical results, and even if we believe the data collected from clinical trials are positive, the results of future research may not be consistent with past positive results, or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; we may not be able to comply with all FDA requests in a timely manner or at all; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading 'Risk Factors' in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law. Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us.
Yahoo
30 minutes ago
- Yahoo
Why FTAI Infrastructure (FIP) Stock Is Up Today
What Happened? Shares of infrastructure investment and operations firm FTAI Infrastructure (NASDAQ:FIP) jumped 3.2% in the morning session after the stock gained ground amid broader positive market sentiment ahead of a busy week for corporate earnings. Notably, the earnings season got off to a strong start: More than 85% of the S&P 500 stocks that reported earnings exceeded expectations, according to FactSet data. This robust performance fueled positive sentiment, suggesting that corporate profitability remained resilient despite ongoing economic uncertainties. After the initial pop the shares cooled down to $6.93, up 2.6% from previous close. Is now the time to buy FTAI Infrastructure? Access our full analysis report here, it's free. What Is The Market Telling Us FTAI Infrastructure's shares are extremely volatile and have had 37 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 3 months ago when the stock dropped 12.1% on the news that stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%, while the baseline 10% tariffs remained in place for all countries. This reminded markets that the global trade environment remained volatile, limiting the potential for sustained gains. Also, President Trump said he was willing to accept pain in the short term, and was aware his policies could cause a recession, but he remained more mindful of a more severe case of economic depression (higher unemployment and prolonged downturn). For investors, this suggested that the administration could prioritize long-term structural shifts over near-term economic stability, further increasing policy-driven risk in the markets. FTAI Infrastructure is down 4.9% since the beginning of the year, and at $6.93 per share, it is trading 32.8% below its 52-week high of $10.31 from July 2024. Investors who bought $1,000 worth of FTAI Infrastructure's shares at the IPO in July 2022 would now be looking at an investment worth $2,308. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Why Privia Health (PRVA) Stock Is Up Today
What Happened? Shares of healthcare tech company Privia Health Group (NASDAQ:PRVA) jumped 3.4% in the morning session as investors anticipated a heavy week of corporate earnings. There was no company-specific news to explain the move, suggesting the physician enablement company's stock was lifted by positive sentiment in the wider market. U.S. stock futures pointed to a higher open, with major indices edging up in early trading. This upbeat mood came as Wall Street braced for a significant number of earnings reports from major U.S. companies. Notably, the earnings season got off to a strong start: More than 85% of the S&P 500 stocks that reported earnings exceeded expectations, according to FactSet data. This robust performance fueled positive sentiment, suggesting that corporate profitability remained resilient despite ongoing economic uncertainties. After the initial pop the shares cooled down to $19.93, up 1.6% from previous close. Is now the time to buy Privia Health? Access our full analysis report here, it's free. What Is The Market Telling Us Privia Health's shares are somewhat volatile and have had 12 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 3 days ago when the stock dropped 5.2% as several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively. Additionally, some pharmaceutical and biotech companies experienced sharp drops following unfavorable news; for instance, Sarepta Therapeutics plunged after a report indicated another patient death tied to its experimental gene therapy, and GSK's blood cancer drug dosage was voted against by the FDA advisory committee. Broader market sentiment, including concerns about rising costs and inadequate pricing for 2025 plans among health insurers, also contributed to the downward pressure on healthcare equities. Privia Health is up 1.5% since the beginning of the year, but at $19.93 per share, it is still trading 22.4% below its 52-week high of $25.69 from March 2025. Investors who bought $1,000 worth of Privia Health's shares at the IPO in April 2021 would now be looking at an investment worth $573.53. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data